Engineering and application of collagen‐binding fibroblast growth factor 2 for sustained release. Issue 1 (10th May 2013)

• Record Type: Journal Article
• Authors: Jeon, Eunyi; Yun, Ye‐Rang; Kim, Hae‐Won; Jang, Jun‐Hyeog
• Is Part Of: Journal of biomedical materials research. Volume 102:Issue 1(2014:Jan.)
• Page Start: 1
• Page End: 7
• Publication Date: 2013-05-10
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.a.34689
• Languages: English
• ISSNs: 1549-3296

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The sustained release of growth factors plays a critical role in therapeutic applications because of the instability of these factors in the body. Here, we designed a fibroblast growth factor 2 (FGF2) fused with a collagen‐binding domain (rhCBD‐FGF2) for collagen‐based sustained release of FGF2.The release profile of rhCBD‐FGF2 showed sustained release from collagen matrices. Further, rhCBD‐FGF2 also stimulated adhesion of the MC3T3‐E1 cells to the collagen matrices. In addition, rhCBD‐FGF2 increased the cell proliferation activity at 3 and 5 days in the MC3T3‐E1 cells attached to the collagen matrices compared to that in the control. Further, rhCBD‐FGF2 significantly induced the osteogenic differentiation of MC3T3‐E1 cells on collagen matrices by up‐regulating the alkaline phosphatase activity at 7 days. These osteogenic differentiation activities were confirmed in gene expression of MC3T3‐E1 cell. Taken together, rhCBD‐FGF2 could specifically bind with collagen matrices, which indicates important advancements in bone tissue engineering. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 102A: 1–7, 2014.</p> </abstract>